<DOC>
	<DOCNO>NCT01783730</DOCNO>
	<brief_summary>This study conduct examine safety profile effectiveness daily clinical practice adalimumab rheumatoid arthritis participant show rapid progression structural damage joint , prior history treatment disease-modifying anti-rheumatic drug biological agent .</brief_summary>
	<brief_title>Assessment Safety Adalimumab Rheumatoid Arthritis Patients Showing Rapid Progression Structural Damage Joints , Who Have Prior History Treatment With Disease-modifying Anti-rheumatic Drugs Biological Agents</brief_title>
	<detailed_description>This multicenter , prospective , observational study adalimumab . Each participant enrol initiate adalimumab treatment follow 24 week discontinuation drug .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . High disease activity , poor prognostic factor ( e.g. , rheumatoid factor [ RF ] positive , anticyclic citrullinated peptide [ CCP ] antibodypositive , bone erosion ) 2 . Combination adalimumab methotrexate start 3 . No prior history treatment diseasemodifying antirheumatic drug 4 . No prior history treatment biological agent 5 . Adalimumab dose accord registered product label 6 . Signed informed consent There specific exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>